ES2901128T3 - Proteína no fucosilada y métodos de la misma - Google Patents

Proteína no fucosilada y métodos de la misma Download PDF

Info

Publication number: ES2901128T3
Authority: ES; Spain
Prior art keywords: seq; tal; dna; cell; fut8
Prior art date: 2014-07-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES15759544T

Other languages

English (en)

Spanish (es)

Inventor

Sohang Chatterjee

Kavitha Iyer Rodrigues

Maloy Ghosh

Sunit Maity

Rajeshwari Pendse

Divya Unnikrishnan

Yogendra Manjunath B M

Jahnabi Hazarika

Sathyabalan M

Pavithra M

Bhargav Prasad

Veeresha K

Prabhat Kumar Pathak

Sanghamitra Bhattacharjee

Pravin Kumar D

Vivek Halan

Sankaranarayanan Srinivasan

Anuradha Hora

Bairavabalakumar N

Karthika Nair

Aswini Thanigaivel

Amol Maliwalave

Bharath R Shenoy

Anisha Kurup

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Zumutor Biologics Inc

Original Assignee

Zumutor Biologics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-07-30

Filing date

2015-07-30

Publication date

2022-03-21

2015-07-30 Application filed by Zumutor Biologics Inc filed Critical Zumutor Biologics Inc

2022-03-21 Application granted granted Critical

2022-03-21 Publication of ES2901128T3 publication Critical patent/ES2901128T3/es

Status Active legal-status Critical Current

2035-07-30 Anticipated expiration legal-status Critical

Links

108090000623 proteins and genes Proteins 0.000 title claims description 203
102000004169 proteins and genes Human genes 0.000 title claims description 175
238000000034 method Methods 0.000 title claims description 68
230000004568 DNA-binding Effects 0.000 claims abstract description 98
125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 81
101710163270 Nuclease Proteins 0.000 claims abstract description 43
239000012636 effector Substances 0.000 claims abstract description 22
230000002103 transcriptional effect Effects 0.000 claims abstract description 6
210000004027 cell Anatomy 0.000 claims description 367
101150023212 fut8 gene Proteins 0.000 claims description 99
108091028043 Nucleic acid sequence Proteins 0.000 claims description 73
102000004190 Enzymes Human genes 0.000 claims description 36
108090000790 Enzymes Proteins 0.000 claims description 36
239000013598 vector Substances 0.000 claims description 26
230000033581 fucosylation Effects 0.000 claims description 22
108091033319 polynucleotide Proteins 0.000 claims description 15
102000040430 polynucleotide Human genes 0.000 claims description 15
239000002157 polynucleotide Substances 0.000 claims description 15
230000000694 effects Effects 0.000 claims description 12
238000013518 transcription Methods 0.000 claims description 9
230000035897 transcription Effects 0.000 claims description 9
108010019236 Fucosyltransferases Proteins 0.000 claims description 7
102000006471 Fucosyltransferases Human genes 0.000 claims description 7
108010073062 Transcription Activator-Like Effectors Proteins 0.000 claims description 7
108010042407 Endonucleases Proteins 0.000 claims description 6
210000004962 mammalian cell Anatomy 0.000 claims description 5
210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 4
102000004533 Endonucleases Human genes 0.000 claims description 3
102100032049 E3 ubiquitin-protein ligase LRSAM1 Human genes 0.000 description 220
238000010459 TALEN Methods 0.000 description 201
235000018102 proteins Nutrition 0.000 description 167
102100021266 Alpha-(1,6)-fucosyltransferase Human genes 0.000 description 94
101000819490 Homo sapiens Alpha-(1,6)-fucosyltransferase Proteins 0.000 description 93
108020004414 DNA Proteins 0.000 description 77
238000003752 polymerase chain reaction Methods 0.000 description 72
108010034897 lentil lectin Proteins 0.000 description 60
239000000047 product Substances 0.000 description 51
235000001014 amino acid Nutrition 0.000 description 50
150000007523 nucleic acids Chemical group 0.000 description 35
238000001890 transfection Methods 0.000 description 33
229940024606 amino acid Drugs 0.000 description 31
239000013612 plasmid Substances 0.000 description 31
150000001413 amino acids Chemical class 0.000 description 30
230000027455 binding Effects 0.000 description 26
239000012131 assay buffer Substances 0.000 description 25
239000002609 medium Substances 0.000 description 25
238000012163 sequencing technique Methods 0.000 description 23
238000003556 assay Methods 0.000 description 22
238000012217 deletion Methods 0.000 description 22
230000037430 deletion Effects 0.000 description 22
238000000684 flow cytometry Methods 0.000 description 22
230000005782 double-strand break Effects 0.000 description 20
239000000203 mixture Substances 0.000 description 20
SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 19
230000006870 function Effects 0.000 description 17
230000035772 mutation Effects 0.000 description 17
239000002773 nucleotide Substances 0.000 description 17
125000003729 nucleotide group Chemical group 0.000 description 17
239000012634 fragment Substances 0.000 description 16
230000004048 modification Effects 0.000 description 16
238000012986 modification Methods 0.000 description 16
238000004458 analytical method Methods 0.000 description 15
230000001580 bacterial effect Effects 0.000 description 15
SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 14
PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 14
230000012010 growth Effects 0.000 description 14
230000014509 gene expression Effects 0.000 description 13
230000003197 catalytic effect Effects 0.000 description 12
239000003153 chemical reaction reagent Substances 0.000 description 12
238000013461 design Methods 0.000 description 12
238000002474 experimental method Methods 0.000 description 12
238000002955 isolation Methods 0.000 description 12
238000000159 protein binding assay Methods 0.000 description 12
230000001225 therapeutic effect Effects 0.000 description 12
108010052285 Membrane Proteins Proteins 0.000 description 11
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 11
229960000723 ampicillin Drugs 0.000 description 11
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 11
238000003780 insertion Methods 0.000 description 11
230000037431 insertion Effects 0.000 description 11
230000002779 inactivation Effects 0.000 description 10
239000000546 pharmaceutical excipient Substances 0.000 description 10
OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 9
241000699802 Cricetulus griseus Species 0.000 description 9
239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 9
230000004075 alteration Effects 0.000 description 9
238000010276 construction Methods 0.000 description 9
230000037433 frameshift Effects 0.000 description 9
239000000499 gel Substances 0.000 description 9
230000003993 interaction Effects 0.000 description 9
230000000670 limiting effect Effects 0.000 description 9
108020004705 Codon Proteins 0.000 description 8
238000001712 DNA sequencing Methods 0.000 description 8
108091092195 Intron Proteins 0.000 description 8
230000008859 change Effects 0.000 description 8
238000010367 cloning Methods 0.000 description 8
238000010790 dilution Methods 0.000 description 8
239000012895 dilution Substances 0.000 description 8
238000005516 engineering process Methods 0.000 description 8
230000006799 invasive growth in response to glucose limitation Effects 0.000 description 8
239000012096 transfection reagent Substances 0.000 description 8
241000588724 Escherichia coli Species 0.000 description 7
108700024394 Exon Proteins 0.000 description 7
239000011543 agarose gel Substances 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 7
231100000221 frame shift mutation induction Toxicity 0.000 description 7
230000001404 mediated effect Effects 0.000 description 7
239000008188 pellet Substances 0.000 description 7
230000008569 process Effects 0.000 description 7
230000008685 targeting Effects 0.000 description 7
230000009466 transformation Effects 0.000 description 7
241000894006 Bacteria Species 0.000 description 6
241000282414 Homo sapiens Species 0.000 description 6
241000508269 Psidium Species 0.000 description 6
238000012790 confirmation Methods 0.000 description 6
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 6
108020001507 fusion proteins Proteins 0.000 description 6
102000037865 fusion proteins Human genes 0.000 description 6
108020004999 messenger RNA Proteins 0.000 description 6
108090000765 processed proteins & peptides Proteins 0.000 description 6
108091008146 restriction endonucleases Proteins 0.000 description 6
238000000870 ultraviolet spectroscopy Methods 0.000 description 6
241000206602 Eukaryota Species 0.000 description 5
LQEBEXMHBLQMDB-UHFFFAOYSA-N GDP-L-fucose Natural products OC1C(O)C(O)C(C)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C3=C(C(N=C(N)N3)=O)N=C2)O1 LQEBEXMHBLQMDB-UHFFFAOYSA-N 0.000 description 5
LQEBEXMHBLQMDB-JGQUBWHWSA-N GDP-beta-L-fucose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C3=C(C(NC(N)=N3)=O)N=C2)O1 LQEBEXMHBLQMDB-JGQUBWHWSA-N 0.000 description 5
102000003886 Glycoproteins Human genes 0.000 description 5
108090000288 Glycoproteins Proteins 0.000 description 5
OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 5
OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 5
MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 5
206010028980 Neoplasm Diseases 0.000 description 5
108091034117 Oligonucleotide Proteins 0.000 description 5
238000012300 Sequence Analysis Methods 0.000 description 5
108010006785 Taq Polymerase Proteins 0.000 description 5
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
238000000246 agarose gel electrophoresis Methods 0.000 description 5
125000000539 amino acid group Chemical group 0.000 description 5
230000003321 amplification Effects 0.000 description 5
230000008901 benefit Effects 0.000 description 5
201000011510 cancer Diseases 0.000 description 5
230000001413 cellular effect Effects 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
238000007822 cytometric assay Methods 0.000 description 5
238000007405 data analysis Methods 0.000 description 5
238000011161 development Methods 0.000 description 5
230000029087 digestion Effects 0.000 description 5
239000003814 drug Substances 0.000 description 5
238000010828 elution Methods 0.000 description 5
230000013595 glycosylation Effects 0.000 description 5
238000006206 glycosylation reaction Methods 0.000 description 5
229950006780 n-acetylglucosamine Drugs 0.000 description 5
238000003199 nucleic acid amplification method Methods 0.000 description 5
238000005457 optimization Methods 0.000 description 5
238000002135 phase contrast microscopy Methods 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
102000004196 processed proteins & peptides Human genes 0.000 description 5
108010054624 red fluorescent protein Proteins 0.000 description 5
238000012216 screening Methods 0.000 description 5
238000007423 screening assay Methods 0.000 description 5
239000000243 solution Substances 0.000 description 5
239000011550 stock solution Substances 0.000 description 5
102100039217 3-ketoacyl-CoA thiolase, peroxisomal Human genes 0.000 description 4
101710186708 Agglutinin Proteins 0.000 description 4
239000004475 Arginine Substances 0.000 description 4
101100013695 Caenorhabditis elegans fut-8 gene Proteins 0.000 description 4
101100153048 Homo sapiens ACAA1 gene Proteins 0.000 description 4
101710146024 Horcolin Proteins 0.000 description 4
101710189395 Lectin Proteins 0.000 description 4
239000006137 Luria-Bertani broth Substances 0.000 description 4
101710179758 Mannose-specific lectin Proteins 0.000 description 4
101710150763 Mannose-specific lectin 1 Proteins 0.000 description 4
101710150745 Mannose-specific lectin 2 Proteins 0.000 description 4
238000012408 PCR amplification Methods 0.000 description 4
239000000910 agglutinin Substances 0.000 description 4
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
210000004899 c-terminal region Anatomy 0.000 description 4
238000002825 functional assay Methods 0.000 description 4
238000010362 genome editing Methods 0.000 description 4
238000002744 homologous recombination Methods 0.000 description 4
230000006801 homologous recombination Effects 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
230000006780 non-homologous end joining Effects 0.000 description 4
102000039446 nucleic acids Human genes 0.000 description 4
108020004707 nucleic acids Proteins 0.000 description 4
150000002482 oligosaccharides Chemical class 0.000 description 4
230000037361 pathway Effects 0.000 description 4
229920001184 polypeptide Polymers 0.000 description 4
230000009467 reduction Effects 0.000 description 4
241000894007 species Species 0.000 description 4
238000010186 staining Methods 0.000 description 4
230000035899 viability Effects 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
108700028369 Alleles Proteins 0.000 description 3
108700010070 Codon Usage Proteins 0.000 description 3
238000007399 DNA isolation Methods 0.000 description 3
102100031780 Endonuclease Human genes 0.000 description 3
108010062427 GDP-mannose 4,6-dehydratase Proteins 0.000 description 3
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
240000004322 Lens culinaris Species 0.000 description 3
235000010666 Lens esculenta Nutrition 0.000 description 3
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
102000018697 Membrane Proteins Human genes 0.000 description 3
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 3
241000251539 Vertebrata <Metazoa> Species 0.000 description 3
108010017070 Zinc Finger Nucleases Proteins 0.000 description 3
239000012574 advanced DMEM Substances 0.000 description 3
210000000628 antibody-producing cell Anatomy 0.000 description 3
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 3
230000034994 death Effects 0.000 description 3
231100000517 death Toxicity 0.000 description 3
238000001976 enzyme digestion Methods 0.000 description 3
239000013604 expression vector Substances 0.000 description 3
238000000605 extraction Methods 0.000 description 3
150000004676 glycans Chemical group 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
238000011081 inoculation Methods 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
230000009871 nonspecific binding Effects 0.000 description 3
230000036961 partial effect Effects 0.000 description 3
229920005862 polyol Polymers 0.000 description 3
150000003077 polyols Chemical class 0.000 description 3
230000002441 reversible effect Effects 0.000 description 3
238000002864 sequence alignment Methods 0.000 description 3
238000011144 upstream manufacturing Methods 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
108091026890 Coding region Proteins 0.000 description 2
230000033616 DNA repair Effects 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
108091092584 GDNA Proteins 0.000 description 2
QGWNDRXFNXRZMB-UUOKFMHZSA-N GDP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O QGWNDRXFNXRZMB-UUOKFMHZSA-N 0.000 description 2
102000002312 GDPmannose 4,6-dehydratase Human genes 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
108010027343 Glycoprotein 6-alpha-L-fucosyltransferase Proteins 0.000 description 2
241000238631 Hexapoda Species 0.000 description 2
229920001612 Hydroxyethyl starch Polymers 0.000 description 2
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
230000004988 N-glycosylation Effects 0.000 description 2
229930193140 Neomycin Natural products 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
102100033118 Phosphatidate cytidylyltransferase 1 Human genes 0.000 description 2
101710178747 Phosphatidate cytidylyltransferase 1 Proteins 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
108010062276 T-Cell Acute Lymphocytic Leukemia Protein 1 Proteins 0.000 description 2
102000011768 T-Cell Acute Lymphocytic Leukemia Protein 1 Human genes 0.000 description 2
108091023045 Untranslated Region Proteins 0.000 description 2
241000589634 Xanthomonas Species 0.000 description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
230000006978 adaptation Effects 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
230000001464 adherent effect Effects 0.000 description 2
102000013529 alpha-Fetoproteins Human genes 0.000 description 2
108010026331 alpha-Fetoproteins Proteins 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
230000008827 biological function Effects 0.000 description 2
239000000090 biomarker Substances 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
239000013599 cloning vector Substances 0.000 description 2
230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
230000009918 complex formation Effects 0.000 description 2
239000002131 composite material Substances 0.000 description 2
238000011109 contamination Methods 0.000 description 2
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
230000002354 daily effect Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
238000006471 dimerization reaction Methods 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
230000009088 enzymatic function Effects 0.000 description 2
210000003527 eukaryotic cell Anatomy 0.000 description 2
230000003203 everyday effect Effects 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
238000009472 formulation Methods 0.000 description 2
238000012239 gene modification Methods 0.000 description 2
235000013922 glutamic acid Nutrition 0.000 description 2
239000004220 glutamic acid Substances 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
101150106565 gmd gene Proteins 0.000 description 2
QGWNDRXFNXRZMB-UHFFFAOYSA-N guanidine diphosphate Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O QGWNDRXFNXRZMB-UHFFFAOYSA-N 0.000 description 2
229940050526 hydroxyethylstarch Drugs 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
230000000415 inactivating effect Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
238000005304 joining Methods 0.000 description 2
239000002502 liposome Substances 0.000 description 2
RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
239000000463 material Substances 0.000 description 2
229960004927 neomycin Drugs 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
229920001542 oligosaccharide Polymers 0.000 description 2
230000008520 organization Effects 0.000 description 2
230000002018 overexpression Effects 0.000 description 2
238000007747 plating Methods 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
238000013207 serial dilution Methods 0.000 description 2
239000012679 serum free medium Substances 0.000 description 2
230000035939 shock Effects 0.000 description 2
238000002741 site-directed mutagenesis Methods 0.000 description 2
125000006850 spacer group Chemical group 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000012360 testing method Methods 0.000 description 2
238000012546 transfer Methods 0.000 description 2
239000011701 zinc Substances 0.000 description 2
229910052725 zinc Inorganic materials 0.000 description 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
MVMSCBBUIHUTGJ-UHFFFAOYSA-N 10108-97-1 Natural products C1=2NC(N)=NC(=O)C=2N=CN1C(C(C1O)O)OC1COP(O)(=O)OP(O)(=O)OC1OC(CO)C(O)C(O)C1O MVMSCBBUIHUTGJ-UHFFFAOYSA-N 0.000 description 1
IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
PZUPAGRIHCRVKN-UHFFFAOYSA-N 5-[5-[3,4-dihydroxy-6-[(3,4,5-trihydroxyoxan-2-yl)oxymethyl]-5-[3,4,5-trihydroxy-6-[(3,4,5-trihydroxyoxan-2-yl)oxymethyl]oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-[(3,4,5-trihydroxyoxan-2-yl)oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound OCC1OC(O)C(O)C(O)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(COC4C(C(O)C(O)CO4)O)O3)O)C(COC3C(C(O)C(O)CO3)O)O2)O)C(COC2C(C(O)C(O)CO2)O)O1 PZUPAGRIHCRVKN-UHFFFAOYSA-N 0.000 description 1
101710146120 Alpha-(1,6)-fucosyltransferase Proteins 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
238000009631 Broth culture Methods 0.000 description 1
101100135641 Caenorhabditis elegans par-3 gene Proteins 0.000 description 1
101100489581 Caenorhabditis elegans par-5 gene Proteins 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
230000008836 DNA modification Effects 0.000 description 1
230000003682 DNA packaging effect Effects 0.000 description 1
231100001074 DNA strand break Toxicity 0.000 description 1
102000052510 DNA-Binding Proteins Human genes 0.000 description 1
101710096438 DNA-binding protein Proteins 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
101000889905 Enterobacteria phage RB3 Intron-associated endonuclease 3 Proteins 0.000 description 1
101000889904 Enterobacteria phage T4 Defective intron-associated endonuclease 3 Proteins 0.000 description 1
101000889900 Enterobacteria phage T4 Intron-associated endonuclease 1 Proteins 0.000 description 1
101000889899 Enterobacteria phage T4 Intron-associated endonuclease 2 Proteins 0.000 description 1
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
108010045674 Fucose-1-phosphate guanylyltransferase Proteins 0.000 description 1
PNHLMHWWFOPQLK-BKUUWRAGSA-N GDP-4-dehydro-6-deoxy-alpha-D-mannose Chemical compound O[C@H]1[C@@H](O)C(=O)[C@@H](C)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C3=C(C(NC(N)=N3)=O)N=C2)O1 PNHLMHWWFOPQLK-BKUUWRAGSA-N 0.000 description 1
MVMSCBBUIHUTGJ-GDJBGNAASA-N GDP-alpha-D-mannose Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=C(NC(=O)C=2N=C1)N)OP(O)(=O)OP(O)(=O)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O MVMSCBBUIHUTGJ-GDJBGNAASA-N 0.000 description 1
101710203794 GDP-fucose transporter Proteins 0.000 description 1
102100023313 GDP-mannose 4,6 dehydratase Human genes 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
230000010558 Gene Alterations Effects 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
229920002527 Glycogen Polymers 0.000 description 1
229930186217 Glycolipid Natural products 0.000 description 1
229920002683 Glycosaminoglycan Polymers 0.000 description 1
108700023372 Glycosyltransferases Proteins 0.000 description 1
108091027305 Heteroduplex Proteins 0.000 description 1
101100013698 Homo sapiens FUT8 gene Proteins 0.000 description 1
101000891113 Homo sapiens T-cell acute lymphocytic leukemia protein 1 Proteins 0.000 description 1
101000625330 Homo sapiens T-cell acute lymphocytic leukemia protein 2 Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
102100040648 L-fucose kinase Human genes 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
108090001090 Lectins Proteins 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
239000012097 Lipofectamine 2000 Substances 0.000 description 1
241000244206 Nematoda Species 0.000 description 1
230000004989 O-glycosylation Effects 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
101710162991 PRKC apoptosis WT1 regulator protein Proteins 0.000 description 1
102100040853 PRKC apoptosis WT1 regulator protein Human genes 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
241000235648 Pichia Species 0.000 description 1
229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
101150055297 SET1 gene Proteins 0.000 description 1
102000000395 SH3 domains Human genes 0.000 description 1
108050008861 SH3 domains Proteins 0.000 description 1
241000235070 Saccharomyces Species 0.000 description 1
101000702553 Schistosoma mansoni Antigen Sm21.7 Proteins 0.000 description 1
101000714192 Schistosoma mansoni Tegument antigen Proteins 0.000 description 1
241000235346 Schizosaccharomyces Species 0.000 description 1
108091058545 Secretory proteins Proteins 0.000 description 1
102000040739 Secretory proteins Human genes 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
101150117538 Set2 gene Proteins 0.000 description 1
241000256248 Spodoptera Species 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
102100040365 T-cell acute lymphocytic leukemia protein 1 Human genes 0.000 description 1
102100025039 T-cell acute lymphocytic leukemia protein 2 Human genes 0.000 description 1
108700019146 Transgenes Proteins 0.000 description 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
101001134239 Trigonella foenum-graecum Protein MANNAN SYNTHESIS-RELATED Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
241000251555 Tunicata Species 0.000 description 1
230000009471 action Effects 0.000 description 1
229960002964 adalimumab Drugs 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
238000003277 amino acid sequence analysis Methods 0.000 description 1
238000000137 annealing Methods 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
238000003491 array Methods 0.000 description 1
125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000003851 biochemical process Effects 0.000 description 1
239000012620 biological material Substances 0.000 description 1
230000008236 biological pathway Effects 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000003560 cancer drug Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
238000011965 cell line development Methods 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
230000033077 cellular process Effects 0.000 description 1
230000007541 cellular toxicity Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000003271 compound fluorescence assay Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000004163 cytometry Methods 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
229910052805 deuterium Inorganic materials 0.000 description 1
239000000539 dimer Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000012361 double-strand break repair Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
108010050663 endodeoxyribonuclease CreI Proteins 0.000 description 1
108010026638 endodeoxyribonuclease FokI Proteins 0.000 description 1
238000007824 enzymatic assay Methods 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
108010083136 fucokinase Proteins 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
238000012268 genome sequencing Methods 0.000 description 1
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
102000045442 glycosyltransferase activity proteins Human genes 0.000 description 1
108700014210 glycosyltransferase activity proteins Proteins 0.000 description 1
230000036541 health Effects 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
229920001477 hydrophilic polymer Polymers 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
229960000598 infliximab Drugs 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000008611 intercellular interaction Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
238000012933 kinetic analysis Methods 0.000 description 1
239000002523 lectin Substances 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000003446 ligand Substances 0.000 description 1
238000001638 lipofection Methods 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
239000012514 monoclonal antibody product Substances 0.000 description 1
239000000178 monomer Substances 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
102000026415 nucleotide binding proteins Human genes 0.000 description 1
108091014756 nucleotide binding proteins Proteins 0.000 description 1
230000009437 off-target effect Effects 0.000 description 1
238000012803 optimization experiment Methods 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
244000000003 plant pathogen Species 0.000 description 1
238000013492 plasmid preparation Methods 0.000 description 1
229920001992 poloxamer 407 Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229940068977 polysorbate 20 Drugs 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
230000012846 protein folding Effects 0.000 description 1
230000030788 protein refolding Effects 0.000 description 1
230000029983 protein stabilization Effects 0.000 description 1
229940124272 protein stabilizer Drugs 0.000 description 1
238000011002 quantification Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000009877 rendering Methods 0.000 description 1
230000028617 response to DNA damage stimulus Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
229960004641 rituximab Drugs 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical class CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 1
238000003151 transfection method Methods 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
238000003146 transient transfection Methods 0.000 description 1
230000032258 transport Effects 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
239000000107 tumor biomarker Substances 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
238000012795 verification Methods 0.000 description 1
102000009310 vitamin D receptors Human genes 0.000 description 1
238000012070 whole genome sequencing analysis Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Biophysics (AREA)
Microbiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Physics & Mathematics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Plant Pathology (AREA)
Public Health (AREA)
Crystallography & Structural Chemistry (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Enzymes And Modification Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

ES15759544T 2014-07-30 2015-07-30 Proteína no fucosilada y métodos de la misma Active ES2901128T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IN3728CH2014		2014-07-30
PCT/IB2015/055777 WO2016016842A1 (fr)	2014-07-30	2015-07-30	Protéine non fucosylée et procédés associés

Publications (1)

Publication Number	Publication Date
ES2901128T3 true ES2901128T3 (es)	2022-03-21

Family

ID=54062778

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES15759544T Active ES2901128T3 (es)	2014-07-30	2015-07-30	Proteína no fucosilada y métodos de la misma

Country Status (6)

Country	Link
US (1)	US10077434B2 (fr)
EP (1)	EP3194583B1 (fr)
JP (1)	JP6796773B2 (fr)
DK (1)	DK3194583T3 (fr)
ES (1)	ES2901128T3 (fr)
WO (1)	WO2016016842A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP6587696B2 (ja) *	2015-05-13	2019-10-09	ズムトールバイオロジクス、インコーポレイテッド	アフコシル化タンパク質、前記タンパク質を発現する細胞、及び関連する方法
CN106701823A (zh) *	2017-01-18	2017-05-24	上海交通大学	生产无岩藻糖单克隆抗体的cho细胞系建立及其应用
CN107881160A (zh)	2017-08-11	2018-04-06	百奥泰生物科技(广州)有限公司	一种由基因组被编辑的cho宿主细胞产生的具有独特糖谱的重组抗体及其制备方法
MY197429A (en) *	2018-08-29	2023-06-16	United Biopharma Inc	Afucosylated antibodies and manufacture thereof
TW202317614A (zh)	2021-06-07	2023-05-01	美商安進公司	使用岩藻糖苷酶控制糖基化蛋白的去岩藻糖基化水平
CN117304308A (zh) *	2022-06-20	2023-12-29	华辉安健（北京）生物科技有限公司	抗乙型肝炎病毒的抗体及其制备和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI0607203A2 (pt) *	2005-02-18	2009-08-25	Medarex Inc	anticorpo anti-cd30 isolado, célula hospedeira, métodos para inibir o crescimento de células cd30+, e, uso de um anticorpo anti-cd30 desfucosilado
CA2692453C (fr)	2007-07-12	2018-01-09	Trevor Collingwood	Procedes et compositions pour inactiver l'expression genique d'alpha-1,6-fucosyltransferase (fut 8)
BR112014027813A2 (pt) *	2012-05-07	2017-08-08	Dow Agrosciences Llc	métodos e composições para integração de transgenes direcionada mediada por nuclease
US9902962B2 (en) *	2012-09-04	2018-02-27	The Scripps Research Institute	Chimeric polypeptides having targeted binding specificity
MX367031B (es)	2012-11-01	2019-08-02	Cellectis	Plantas para la produccion de proteinas terapeuticas.

2015
- 2015-07-30 JP JP2017525678A patent/JP6796773B2/ja active Active
- 2015-07-30 DK DK15759544.8T patent/DK3194583T3/da active
- 2015-07-30 US US15/500,509 patent/US10077434B2/en active Active
- 2015-07-30 ES ES15759544T patent/ES2901128T3/es active Active
- 2015-07-30 EP EP15759544.8A patent/EP3194583B1/fr active Active
- 2015-07-30 WO PCT/IB2015/055777 patent/WO2016016842A1/fr not_active Ceased

Also Published As

Publication number	Publication date
JP6796773B2 (ja)	2020-12-09
WO2016016842A1 (fr)	2016-02-04
US20170306305A1 (en)	2017-10-26
JP2017526384A (ja)	2017-09-14
DK3194583T3 (da)	2021-12-20
EP3194583A1 (fr)	2017-07-26
US10077434B2 (en)	2018-09-18
EP3194583B1 (fr)	2021-09-15

Publication	Publication Date	Title
ES2712303T3 (es)	2019-05-10	Dominio de unión a ADN del sistema CRISPR para la producción de proteínas no fucosiladas y parcialmente fucosiladas
ES2901128T3 (es)	2022-03-21	Proteína no fucosilada y métodos de la misma
US11267899B2 (en)	2022-03-08	Afucosylated protein, cell expressing said protein and associated methods
ES2875274T3 (es)	2021-11-10	Procedimientos de preparación de formas fucosiladas y afucosiladas de una proteína
Malphettes et al.	2010	Highly efficient deletion of FUT8 in CHO cell lines using zinc‐finger nucleases yields cells that produce completely nonfucosylated antibodies
CN103597073B (zh)	2019-06-07	低岩藻糖细胞系及其应用
US8025879B2 (en)	2011-09-27	Modified glycoproteins and uses thereof
ES2738641T3 (es)	2020-01-24	Producción de proteínas terapéuticas en células de mamífero modificadas genéticamente
JP2022058603A (ja)	2022-04-12	Ｆｃ含有タンパク質の発現
CN109072236A (zh)	2018-12-21	用于生产分泌蛋白质的哺乳动物细胞
JP2020202832A (ja)	2020-12-24	非フコシル化タンパク質および方法
Ang	2014	Production of a camelid antibody in CHO cells and its potential for the in vitro modification of its N-glycan using N-acetylglucosaminyltransferase III produced in insect cells
HK1191053A (en)	2014-07-18	Low fucose cell lines and uses thereof
HK40008183A (en)	2020-06-12	Low fucose cell lines and uses thereof
HK1191053B (zh)	2020-04-17	低岩藻糖细胞系及其应用